Pancreatic Cancer Research

ResearcherMayo ClinicActive in the last 2 years

Masao Tanaka

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-8942-2933; OpenAlex author ID A5078409741. Sources: OpenAlex.

Their work

Papers
58 (first author 2, last author 42)
Trials
0
Grants
0
Labs led
2
Collaborators
152
Papers, trials and grants by year

2011: 8 papers · 2012: 7 papers · 2013: 13 papers · 2014: 12 papers · 2015: 6 papers · 2016: 5 papers · 2017: 4 papers · 2018: 2 papers · 2019: none · 2020: none · 2021: none · 2022: none · 2023: none · 2024: none · 2025: none · 2026: 1 paper

Papers 50 of 58

  1. Comparative Study of Pathological and Imaging Findings in High-Grade Pancreatic Intraepithelial Neoplasia: A Multicenter Analysis by the Japan Study Group on E… Last author DOI 10.1097/mpa.0000000000002710↗
  2. Intraductal Papillary Mucinous Neoplasm as the Focus for Early Detection of Pancreatic Cancer Co-author DOI 10.1053/j.gastro.2018.01.014↗
  3. Intraductal Papillary Mucinous Neoplasm of the Pancreas as the Main Focus for Early Detection of Pancreatic Adenocarcinoma. Co-author DOI 10.1097/mpa.0000000000001047↗
  4. Updated results from GEST study: a randomized, three-arm phase III study for advanced pancreatic cancer. Last author DOI 10.1007/s00432-017-2349-y↗
  5. Randomised phase II trial of irinotecan plus S-1 in patients with gemcitabine-refractory pancreatic cancer. Co-author DOI 10.1038/bjc.2016.436↗
  6. S100P in Duodenal Fluid Is a Useful Diagnostic Marker for Pancreatic Ductal Adenocarcinoma. Last author DOI 10.1097/mpa.0000000000000940↗
  7. Health-related quality of life in a randomised phase III study of gemcitabine plus S-1, S-1 alone and gemcitabine alone for locally advanced or metastatic panc… Last author DOI 10.1136/esmoopen-2016-000151↗
  8. Nuclear expression of Y-box binding protein-1 is associated with poor prognosis in patients with pancreatic cancer and its knockdown inhibits tumor growth and … Co-author DOI 10.1002/ijc.30075↗
  9. CD146 attenuation in cancer-associated fibroblasts promotes pancreatic cancer progression. Last author DOI 10.1002/mc.22409↗
  10. Clinical outcome of elderly patients with unresectable pancreatic cancer treated with gemcitabine plus S-1, S-1 alone, or gemcitabine alone: Subgroup analysis … Co-author DOI 10.1016/j.ejca.2015.11.002↗
  11. Clinicopathological Characteristics of Young Patients With Pancreatic Cancer: An Analysis of Data From Pancreatic Cancer Registry of Japan Pancreas Society. Co-author DOI 10.1097/mpa.0000000000000636↗
  12. Unexpected Side Effects of a High S-1 Dose: Subanalysis of a Phase III Trial Comparing Gemcitabine, S-1 and Combinatorial Treatments for Advanced Pancreatic Ca… Co-author DOI 10.1159/000446989↗
  13. Anterior gradient 2 downregulation in a subset of pancreatic ductal adenocarcinoma is a prognostic factor indicative of epithelial-mesenchymal transition. Co-author DOI 10.1038/labinvest.2014.138↗
  14. Clinical significance of GNAS mutation in intraductal papillary mucinous neoplasm of the pancreas with concomitant pancreatic ductal adenocarcinoma. Last author DOI 10.1097/mpa.0000000000000258↗
  15. Early detection of sporadic pancreatic cancer: summative review. Co-author DOI 10.1097/mpa.0000000000000368↗
  16. Predictors and Diagnostic Strategies for Early-Stage Pancreatic Ductal Adenocarcinoma: A Retrospective Study. Last author DOI 10.1097/mpa.0000000000000393↗
  17. TM4SF1 as a prognostic marker of pancreatic ductal adenocarcinoma is involved in migration and invasion of cancer cells. Last author DOI 10.3892/ijo.2015.3022↗
  18. Significance of expression of glucagon-like peptide 1 receptor in pancreatic cancer. Last author DOI 10.3892/or.2015.4138↗
  19. Improved survival with combined gemcitabine and S-1 for locally advanced pancreatic cancer: pooled analysis of three randomized studies. Co-author DOI 10.1002/jhbp.130↗
  20. Role of ERCP in the era of EUS-FNA for preoperative cytological confirmation of resectable pancreatic ductal adenocarcinoma. Last author DOI 10.1007/s00595-014-0845-0↗
  21. Follicular pancreatitis, report of a case clinically mimicking pancreatic cancer and literature review. Co-author DOI 10.1016/j.prp.2013.09.005↗
  22. Intraoperative irrigation cytology of the remnant pancreas to detect remnant distinct pancreatic ductal adenocarcinoma in patients with intraductal papillary m… Last author DOI 10.1016/j.surg.2013.06.059↗
  23. Mass spectrometry-based metabolic profiling of gemcitabine-sensitive and gemcitabine-resistant pancreatic cancer cells. Last author DOI 10.1097/mpa.0000000000000092↗
  24. Reoxygenation from chronic hypoxia promotes metastatic processes in pancreatic cancer through the Hedgehog signaling. Co-author DOI 10.1111/cas.12348↗
  25. Profiling of autoantibodies in sera of pancreatic cancer patients. Last author DOI 10.1245/s10434-014-3574-0↗
  26. Micro RNA-373 is down-regulated in pancreatic cancer and inhibits cancer cell invasion. Last author DOI 10.1245/s10434-014-3676-8↗
  27. CD166/ALCAM expression is characteristic of tumorigenicity and invasive and migratory activities of pancreatic cancer cells. Last author DOI 10.1371/journal.pone.0107247↗
  28. Key endoscopic ultrasound features of pancreatic ductal adenocarcinoma smaller than 20 mm. Co-author DOI 10.3109/00365521.2013.878745↗
  29. Peritoneal myofibroblasts at metastatic foci promote dissemination of pancreatic cancer. Last author DOI 10.3892/ijo.2014.2391↗
  30. Hepaticocholecystojejunostomy as effective palliative biliary bypass for unresectable pancreatic cancer. Last author PMID 24895820↗
  31. Role of endoscopic retrograde pancreatography for early detection of pancreatic ductal adenocarcinoma concomitant with intraductal papillary mucinous neoplasm … Last author DOI 10.1007/s00534-012-0541-7↗
  32. Surgery for chronic pancreatitis decreases the risk for pancreatic cancer: a multicenter retrospective analysis. First author DOI 10.1016/j.surg.2012.08.005↗
  33. MAL2 expression predicts distant metastasis and short survival in pancreatic cancer. Last author DOI 10.1016/j.surg.2013.03.010↗
  34. A minimally invasive and simple screening test for detection of pancreatic ductal adenocarcinoma using biomarkers in duodenal juice. Last author DOI 10.1097/mpa.0b013e3182649979↗
  35. Kindlin-2 expression in peritumoral stroma is associated with poor prognosis in pancreatic ductal adenocarcinoma. Last author DOI 10.1097/mpa.0b013e318279bd66↗
  36. Migratory activity of CD105+ pancreatic cancer cells is strongly enhanced by pancreatic stellate cells. Last author DOI 10.1097/mpa.0b013e318293e7bd↗
  37. Pirfenidone inhibits pancreatic cancer desmoplasia by regulating stellate cells. Last author DOI 10.1158/0008-5472.can-12-3180↗
  38. Pancreatic Cancer: Clinical Significance of Biomarkers. Last author DOI 10.1159/000354996↗
  39. Randomized phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan… Last author DOI 10.1200/jco.2012.43.3680↗
  40. Kindlin-1 expression is involved in migration and invasion of pancreatic cancer. Last author DOI 10.3892/ijo.2013.1838↗
  41. S100A4 mRNA expression level is a predictor of radioresistance of pancreatic cancer cells. Last author DOI 10.3892/or.2013.2636↗
  42. Combination therapy of portal vein resection and adjuvant gemcitabine improved prognosis of advanced pancreatic cancer. Last author DOI 10.1016/j.jss.2011.11.714↗
  43. Unresectable pancreatic ductal adenocarcinoma in the remnant pancreas diagnosed during every-6-month surveillance after resection of branch duct intraductal pa… Last author DOI 10.6092/1590-8577/1494↗
  44. Japan Pancreatic Cancer Registry; 30th year anniversary: Japan Pancreas Society. Last author DOI 10.1097/mpa.0b013e318258055c↗
  45. Significance of combination therapy of zoledronic acid and gemcitabine on pancreatic cancer. Last author DOI 10.1111/j.1349-7006.2011.02113.x↗
  46. Claudin-4 expression predicts survival in pancreatic ductal adenocarcinoma. Last author DOI 10.1245/s10434-011-1970-2↗
  47. MicroRNA-10a is overexpressed in human pancreatic cancer and involved in its invasiveness partially via suppression of the HOXA1 gene. Last author DOI 10.1245/s10434-012-2252-3↗
  48. Pancreatic cancer cells enhance the ability of collagen internalization during epithelial-mesenchymal transition. Last author DOI 10.1371/journal.pone.0040434↗
  49. CD271⁺ subpopulation of pancreatic stellate cells correlates with prognosis of pancreatic cancer and is regulated by interaction with cancer cells. Last author DOI 10.1371/journal.pone.0052682↗
  50. [Diabetes and pancreatic cancer]. Last author PMID 23156459↗

Closest collaborators

The 25 strongest of 152 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Takao Ohtsuka · 31 shared papers, 2011–2026 · strength 1.34
  2. Kenoki Ohuchida · 27 shared papers, 2011–2017 · strength 0.98
  3. Yoshinao Oda · 17 shared papers, 2011–2017 · strength 0.72
  4. Noboru Ideno · 10 shared papers, 2013–2026 · strength 0.56
  5. Masafumi Nakamura · 11 shared papers, 2012–2017 · strength 0.44
  6. Lin Cui · 12 shared papers, 2011–2016 · strength 0.43
  7. Koji Shindo · 10 shared papers, 2012–2015 · strength 0.38
  8. Junji Ueda · 10 shared papers, 2011–2015 · strength 0.37
  9. Shingo Kozono · 10 shared papers, 2012–2014 · strength 0.33
  10. Naoki Ikenaga · 10 shared papers, 2011–2014 · strength 0.33
  11. Kenji Fujiwara · 9 shared papers, 2012–2015 · strength 0.32
  12. Masayuki Kitano · 3 shared papers, 2013–2026 · strength 0.30
  13. Shujiro Yazumi · 2 shared papers, 2016–2026 · strength 0.28
  14. Yasuhisa Mori · 7 shared papers, 2013–2017 · strength 0.28
  15. Hayato Fujita · 9 shared papers, 2011–2013 · strength 0.26
  16. Shinichi Egawa · 6 shared papers, 2012–2017 · strength 0.26
  17. Akio Yanagisawa · 2 shared papers, 2012–2026 · strength 0.26
  18. Ming Zhao · 7 shared papers, 2011–2016 · strength 0.25
  19. Takuji Okusaka · 6 shared papers, 2012–2017 · strength 0.25
  20. Keiji Hanada · 2 shared papers, 2011–2026 · strength 0.25
  21. Toru Furukawa · 2 shared papers, 2011–2026 · strength 0.25
  22. Shinichi Ohkawa · 5 shared papers, 2013–2017 · strength 0.24
  23. Hiroshi Kono · 7 shared papers, 2013–2014 · strength 0.24
  24. Atsushi Kanno · 1 shared paper, 2026 · strength 0.22
  25. Mamoru Takenaka · 1 shared paper, 2026 · strength 0.22

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.